Joshua Zeidner

@LeukDocJZ

Oncologist specializing in Leukemia & Myeloid Malignancies, Clinical Trialist, Assistant Professor at UNC Lineberger. Tweets are my own.

Chapel Hill, NC
Vrijeme pridruživanja: svibanj 2019.

Tweetovi

Blokirali ste korisnika/cu @LeukDocJZ

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LeukDocJZ

  1. 24. sij

    Fascinating paper by and colleagues in showing that monocytic phenotypes (ie M5) do not respond well to Venetoclax due to low BCL-2 & MCL-1 dependence. Targeting MCL-1 (directly or indirectly) represents a rational approach after Tx w/Ven (esp M5).

    Poništi
  2. 24. sij

    Grateful for our amazing Leukemia Research Team! Without your critical support, we would not be able to conduct cutting edge clinical trials and strive to find cures for leukemia(s)! Thanks for all that you do!

    Poništi
  3. 23. sij

    My intern arrives to rounds today with APL sneakers...and I can even detect an Auer rod through the name! Bad omen for the Leukemia service? I told him to differentiate his sneakers to a different brand!

    Poništi
  4. proslijedio/la je Tweet
    22. sij

    Lineberger's Christopher Dittus, DO, MPH, is the editor of a new book that provides a comprehensive review of how to diagnose and manage rare lymphomas.

    Poništi
  5. 3. sij

    Grateful for the support of , mentorship from Dr. Ivana Gojo , translational correlates spearheaded by Dr. Hanna Knaus and Dr. Leo Luznik. Great collaboration with Dr. Amer Zeidan ,

    Prikaži ovu nit
    Poništi
  6. 3. sij

    8/ Ultimately, we hope these findings will provide a springboard for the next generation of clinical trials with Pomalidomide & other immune modulatory strategies at early recovery post-induction chemo in AML to improve clinical outcomes.

    Prikaži ovu nit
    Poništi
  7. 3. sij

    7/ Pomalidomide led to significant decrease in Aiolos and impacted T cell differentiation and activation, supporting our translational hypothesis. Moreover, Pom decreased suppressive Treg gene signatures while activating cell cycle pathways in T cell subpopulations.

    Prikaži ovu nit
    Poništi
  8. 3. sij

    6/ Although small #'s, we saw clinical activity with the addition of pomalidomide- overall 75% CR and 77% CR/CRi among those Tx with Pom. We saw impressive clinical activity in secondary AML (71% CR), AML with MRC (85% CR), and >=60 years (82% CR) which appeared > control.

    Prikaži ovu nit
    Poništi
  9. 3. sij

    5/ We found that pomalidomide was able to be safely added at the time of ELR post-induction chemo. MTD = 4 mg x 21 days, most common toxicities (mainly G1-2) = rash, liver function test abnormalities, mucositis and fever.

    Prikaži ovu nit
    Poništi
  10. 3. sij

    4/ We hypothesized that immune modulation during a vulnerable time period after induction chemotherapy at ELR may synergize with induction chemotherapy and improve outcomes in AML. To that end, we studied the addition of pomalidomide at early recovery after induction chemo.

    Prikaži ovu nit
    Poništi
  11. 3. sij

    3/ So...we asked the question, can we intervene with immune modulation prior to full recovery to counteract this dysfunctional immune state in AML?

    Prikaži ovu nit
    Poništi
  12. 3. sij

    2/ We also showed that CD8+ T cells in AML at Dx are exhausted and senescent & persisted in those who did not respond to induction chemo whereas the T cell function was restored in patients who achieved CR.

    Prikaži ovu nit
    Poništi
  13. 3. sij

    1/ The background of this study is that our group previously found that early lymphocyte recovery (~day 21) after induction timed sequential therapy for AML is dominated by an expanded oligoclonal population of Tregs that are immunosuppressive.

    Prikaži ovu nit
    Poništi
  14. 3. sij

    Excited to start the New Year with 👉 Phase 1 study of pomalidomide after induction chemo in newly dx AML. Blood, sweat, & tears went into this study over last several years! Thankful for for funding me!

    Prikaži ovu nit
    Poništi
  15. 20. pro 2019.

    Excellent and impactful paper by & colleagues showing the importance of MRD and conditioning intensity in allogeneic transplant for AML. If NGS MRD positive, MAC significantly improves OS and relapse risk compared to RIC. Figure 3 most telling.

    Poništi
  16. 20. pro 2019.

    Best Holiday gift ever!! Thanks

    Poništi
  17. proslijedio/la je Tweet
    12. pro 2019.

    Asciminib was active in heavily pretreated patients with CML who had resistance to or unacceptable side effects from TKIs, including patients in whom ponatinib had failed and those with a T315I mutation.

    Poništi
  18. 10. pro 2019.

    It is rare to witness true practice changing presentations at ASH- oral Azacitidine improves OS and RFS in older AML pts in CR/CRi after intensive induction and consolidation. Favorable-risk was excluded however. Congratulations Andrew Wei & investigators!

    Poništi
  19. proslijedio/la je Tweet
    9. pro 2019.

    CONGRESS | |Another interesting talk, from presents final results of high dose cytarabine followed by pembrolizumab in R/R AML. Safe with ORR of 46% and CR 38%

    Prikaži ovu nit
    Poništi
  20. 9. pro 2019.

    Checkpoint Inhibitor session in AML- Ivana Gojo presenting data on Aza + Pembro- impressive clinical activity in newly diagnosed elderly AML. Proud to be part of this important study!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·